TY  - BOOK
AU  - Wortmann, Glenn W
TI  - Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients
SN  - 1664-3224
PY  - 2024///
KW  - *Autoantibodies
KW  - *Complement Activation
KW  - *COVID-19
KW  - *Immunoglobulin M
KW  - *SARS-CoV-2
KW  - Adult
KW  - Aged
KW  - Autoantibodies/bl [Blood]
KW  - Autoantibodies/im [Immunology]
KW  - CD4-Positive T-Lymphocytes/im [Immunology]
KW  - Complement Activation/im [Immunology]
KW  - Complement C3b/im [Immunology]
KW  - COVID-19/bl [Blood]
KW  - COVID-19/im [Immunology]
KW  - Female
KW  - Humans
KW  - Immunoglobulin M/bl [Blood]
KW  - Immunoglobulin M/im [Immunology]
KW  - Lymphocytes/im [Immunology]
KW  - Lymphopenia/bl [Blood]
KW  - Lymphopenia/im [Immunology]
KW  - Male
KW  - Middle Aged
KW  - Prevalence
KW  - SARS-CoV-2/im [Immunology]
KW  - Automated
KW  - MedStar Washington Hospital Center
KW  - Medicine/Infectious Disease
KW  - Journal Article
KW  - Research Support, Non-U.S. Gov't
N2  - Discussion: IgM ALAb and complement activation against lymphocytes may contribute to the acute lymphopenia observed in COVID-19 patients. Copyright © 2024 Perez-Diez, Liu, Calderon, Bennett, Lisco, Kellog, Galindo, Memoli, Rocco, Epling, Laidlaw, Sneller, Manion, Wortmann, Poon, Kumar and Sereti; Introduction: COVID-19 patients can develop autoantibodies against a variety of secreted and membrane proteins, including some expressed on lymphocytes. However, it is unclear what proportion of patients might develop anti-lymphocyte antibodies (ALAb) and what functional relevance they might have; Methods: We evaluated the presence and lytic function of ALAb in the sera of a cohort of 85 COVID-19 patients (68 unvaccinated and 17 vaccinated) assigned to mild (N=63), or moderate/severe disease (N=22) groups. Thirty-seven patients were followed-up after recovery. We also analyzed in vivo complement deposition on COVID-19 patients' lymphocytes and examined its correlation with lymphocyte numbers during acute disease; Results: Compared with healthy donors (HD), patients had an increased prevalence of IgM ALAb, which was significantly higher in moderate/severe disease patients and persisted after recovery. Sera from IgM ALAb+ patients exhibited complement-dependent cytotoxicity (CDC) against HD lymphocytes. Complement protein C3b deposition on patients' CD4 T cells was inversely correlated with CD4 T cell numbers. This correlation was stronger in moderate/severe disease patients
UR  - https://dx.doi.org/10.3389/fimmu.2024.1352330
ER  -